# CRISPR Therapeutics AG (CRSP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $55.79, market value $5.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). CRISPR Therapeutics AG reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 402.8×**. Each dollar of revenue is priced at 402.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.1×**. The shares trade at 3.1× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -6.9%** (5-yr avg -5.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -30.3%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -26.8%**. Return on all capital, debt included, is -26.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -19.9%**. Each dollar of assets produces -19.9% of profit.

## Growth
- **Revenue growth (1 yr): -90.6%** (3-yr 43.1%/yr, 5-yr 37.3%/yr). Revenue fell 90.6% over the last year, against 37.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -49.1%**. Earnings per share fell 49.1%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.7×**. It would take 0.7 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 9.65**. A Z-score of 9.65 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. CRISPR Therapeutics AG does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (18 analysts). 18 analysts cover CRISPR Therapeutics AG; the consensus is buy, with an average price target of $87.56 (+57% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.8%** (YTD 6.4%, 3-mo 7.6%). The shares are up 5.8% over twelve months including dividends.
- **From 52-week high: -28.9%** (26.5% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.83** (volatility 60%). Beta of 1.83 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRSP · Page: https://foliofundamentals.com/stocks/crsp

Not investment advice.